An elderly patient with mycosis fungoides successfully treated with chronic low-dose oral etoposide therapy [2]

Clinical and Experimental Dermatology

Volumn 29, Issue 1, 2004, Pages 91-92

  Onozuka, T ^a   Yokota, K ^a   Kawashima, T ^a   Shimada, H ^a   Kodama, K ^a   Kobayashi, H ^a   Shimizu, H ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; PREDNISOLONE; RETINOID;

BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; ELDERLY CARE; ELECTRON BEAM; HISTOPATHOLOGY; HUMAN; LETTER; MYCOSIS FUNGOIDES; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUVA; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0842265704     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01373.x     Document Type: Letter

References (4)

1. Bunn PA Jr, Hoffman SJ, Norris D et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
2. Greco FA, Johnson DH, Hainsworth JD. Chronic daily administration of oral etoposide. Semin Oncol 1990; 17: 71-4.
3. Hainsworth JD, Johnson DH, Frazier SR et al. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990; 26: 818-21.
4. Sakoda H, Yoshida H, Usami M et al. Chronic daily oral low-dose etoposide therapy for an aged patient with aggressive lymphoma: a successful case report. Gan Kagaku Ryoho Jap 1993; 20: 1079-82.